ID   MECOM_HUMAN             Reviewed;        1230 AA.
AC   Q03112; A1L4F3; A8KA00; B7Z8W7; B7ZLQ3; B7ZLQ4; C9JAK0; D3DNP7; E7EQ57;
AC   Q13465; Q13466; Q16122; Q5HYI1; Q6FH90; Q6MZS6; Q8NEI5; Q99917;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 3.
DT   26-FEB-2020, entry version 194.
DE   RecName: Full=Histone-lysine N-methyltransferase MECOM {ECO:0000305};
DE            EC=2.1.1.- {ECO:0000250|UniProtKB:P14404};
DE   AltName: Full=Ecotropic virus integration site 1 protein homolog;
DE            Short=EVI-1;
DE   AltName: Full=MDS1 and EVI1 complex locus protein {ECO:0000305};
DE   AltName: Full=Myelodysplasia syndrome 1 protein;
DE   AltName: Full=Myelodysplasia syndrome-associated protein 1;
GN   Name=MECOM {ECO:0000312|HGNC:HGNC:3498};
GN   Synonyms=EVI1 {ECO:0000303|PubMed:8643684}, MDS1
GN   {ECO:0000303|PubMed:8643684}, PRDM3 {ECO:0000303|PubMed:22939622};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING.
RX   PubMed=2115646;
RA   Morishita K., Parganas E., Douglass E.C., Ihle J.N.;
RT   "Unique expression of the human Evi-1 gene in an endometrial carcinoma cell
RT   line: sequence of cDNAs and structure of alternatively spliced
RT   transcripts.";
RL   Oncogene 5:963-971(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 9), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   14-127 (ISOFORMS 2/7/8), AND CHROMOSOMAL TRANSLOCATION WITH AML1.
RC   TISSUE=Kidney, and Pancreas;
RX   PubMed=8643684; DOI=10.1073/pnas.93.4.1642;
RA   Fears S., Mathieu C., Zeleznik-Le N., Huang S., Rowley J.D., Nucifora G.;
RT   "Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as
RT   in myeloid leukemia and produces a new member of the PR domain family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:1642-1647(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=11050005;
RA   Mochizuki N., Shimizu S., Nagasawa T., Tanaka H., Taniwaki M., Yokota J.,
RA   Morishita K.;
RT   "A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1
RT   gene and is transcriptionally activated in t(1;3)(p36;q21)-positive
RT   leukemia cells.";
RL   Blood 96:3209-3214(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 8).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,
RA   Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S.,
RA   Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S.,
RA   Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H.,
RA   Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M.,
RA   Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M.,
RA   Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y.,
RA   Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N.,
RA   Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S.,
RA   Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T.,
RA   Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M.,
RA   Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y.,
RA   Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y.,
RA   Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T.,
RA   Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Adipose tissue, and Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Blocker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Kohrer K., Ottenwalder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 6), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9), AND NUCLEOTIDE SEQUENCE [LARGE
RP   SCALE MRNA] OF 704-1230 (ISOFORM 7).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 13-1230 (ISOFORM 7), AND CHROMOSOMAL
RP   TRANSLOCATION WITH RUNX1 IN CHRONIC MYELOCYTIC LEUKEMIA.
RX   PubMed=8313895;
RA   Mitani K., Ogawa S., Tanaka T., Miyoshi H., Kurokawa M., Mano H.,
RA   Yazaki Y., Ohki M., Hirai H.;
RT   "Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes
RT   blastic crisis in chronic myelocytic leukemia.";
RL   EMBO J. 13:504-510(1994).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1149-1191.
RX   PubMed=8700545;
RA   Ogawa S., Kurokawa M., Tanaka T., Mitani K., Inazawa J., Hangaishi A.,
RA   Tanaka K., Matsuo Y., Minowada J., Tsubota T., Yazaki Y., Hirai H.;
RT   "Structurally altered Evi-1 protein generated in the 3q21q26 syndrome.";
RL   Oncogene 13:183-191(1996).
RN   [12]
RP   FUNCTION, ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), HOMOOLIGOMERIZATION,
RP   INTERACTION WITH CTBP1 AND SMAD3, AND SUBCELLULAR LOCATION.
RX   PubMed=15897867; DOI=10.1038/sj.onc.1208754;
RA   Nitta E., Izutsu K., Yamaguchi Y., Imai Y., Ogawa S., Chiba S.,
RA   Kurokawa M., Hirai H.;
RT   "Oligomerization of Evi-1 regulated by the PR domain contributes to
RT   recruitment of corepressor CtBP.";
RL   Oncogene 24:6165-6173(2005).
RN   [13]
RP   FUNCTION IN TGF-BETA SIGNALING, INTERACTION WITH SMAD3 AND SMAD4, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=9665135; DOI=10.1038/27945;
RA   Kurokawa M., Mitani K., Irie K., Matsuyama T., Takahashi T., Chiba S.,
RA   Yazaki Y., Matsumoto K., Hirai H.;
RT   "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.";
RL   Nature 394:92-96(1998).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH MAPK8 AND MAPK9.
RX   PubMed=10856240; DOI=10.1093/emboj/19.12.2958;
RA   Kurokawa M., Mitani K., Yamagata T., Takahashi T., Izutsu K., Ogawa S.,
RA   Moriguchi T., Nishida E., Yazaki Y., Hirai H.;
RT   "The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents
RT   stress-induced cell death.";
RL   EMBO J. 19:2958-2968(2000).
RN   [16]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=16462766; DOI=10.1038/sj.onc.1209403;
RA   Liu Y., Chen L., Ko T.C., Fields A.P., Thompson E.A.;
RT   "Evi1 is a survival factor which conveys resistance to both TGFbeta- and
RT   taxol-mediated cell death via PI3K/AKT.";
RL   Oncogene 25:3565-3575(2006).
RN   [17]
RP   FUNCTION, ACETYLATION, INTERACTION WITH CREBBP; CTBP1; KAT2B AND HISTONE
RP   DEACETYLASES, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 743-ASP-LEU-744 AND
RP   774-ASP-LEU-775.
RX   PubMed=11568182; DOI=10.1074/jbc.M106733200;
RA   Chakraborty S., Senyuk V., Sitailo S., Chi Y., Nucifora G.;
RT   "Interaction of EVI1 with cAMP-responsive element-binding protein-binding
RT   protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible
RT   acetylation of EVI1 and in co-localization in nuclear speckles.";
RL   J. Biol. Chem. 276:44936-44943(2001).
RN   [18]
RP   FUNCTION.
RX   PubMed=19767769; DOI=10.1038/onc.2009.288;
RA   Shimabe M., Goyama S., Watanabe-Okochi N., Yoshimi A., Ichikawa M.,
RA   Imai Y., Kurokawa M.;
RT   "Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and
RT   leukemic cells.";
RL   Oncogene 28:4364-4374(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.D., Yates J.R.;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1039, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.
RX   PubMed=22939622; DOI=10.1016/j.cell.2012.06.048;
RA   Pinheiro I., Margueron R., Shukeir N., Eisold M., Fritzsch C.,
RA   Richter F.M., Mittler G., Genoud C., Goyama S., Kurokawa M., Son J.,
RA   Reinberg D., Lachner M., Jenuwein T.;
RT   "Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian
RT   heterochromatin integrity.";
RL   Cell 150:948-960(2012).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-624; SER-726; SER-1037 AND
RP   SER-1039, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-190; LYS-555; LYS-685; LYS-721;
RP   LYS-735; LYS-752; LYS-787; LYS-1127; LYS-1132 AND LYS-1152, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-190; LYS-555; LYS-685; LYS-721;
RP   LYS-877; LYS-1053; LYS-1132 AND LYS-1152, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [25]
RP   INVOLVEMENT IN RUSAT2, VARIANTS RUSAT2 TRP-929; ARG-930 AND ALA-935, AND
RP   CHARACTERIZATION OF VARIANTS RUSAT2 TRP-929; ARG-930 AND ALA-935.
RX   PubMed=26581901; DOI=10.1016/j.ajhg.2015.10.010;
RA   Niihori T., Ouchi-Uchiyama M., Sasahara Y., Kaneko T., Hashii Y., Irie M.,
RA   Sato A., Saito-Nanjo Y., Funayama R., Nagashima T., Inoue S., Nakayama K.,
RA   Ozono K., Kure S., Matsubara Y., Imaizumi M., Aoki Y.;
RT   "Mutations in MECOM, encoding oncoprotein EVI1, cause radioulnar synostosis
RT   with amegakaryocytic thrombocytopenia.";
RL   Am. J. Hum. Genet. 97:848-854(2015).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-99; LYS-190; LYS-249; LYS-292;
RP   LYS-367; LYS-374; LYS-430; LYS-523; LYS-543; LYS-547; LYS-555; LYS-622;
RP   LYS-635; LYS-663; LYS-685; LYS-721; LYS-731; LYS-732; LYS-735; LYS-749;
RP   LYS-752; LYS-760; LYS-787; LYS-800; LYS-801; LYS-835; LYS-844; LYS-846;
RP   LYS-877; LYS-1018; LYS-1053; LYS-1056; LYS-1120; LYS-1127; LYS-1132;
RP   LYS-1149; LYS-1152; LYS-1176 AND LYS-1184, SUMOYLATION [LARGE SCALE
RP   ANALYSIS] AT LYS-658 (ISOFORM 1), SUMOYLATION [LARGE SCALE ANALYSIS] AT
RP   LYS-846 (ISOFORMS 2 AND 8), SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-202
RP   AND LYS-723 (ISOFORM 4), SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-138
RP   (ISOFORM 6), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: [Isoform 1]: Functions as a transcriptional regulator binding
CC       to DNA sequences in the promoter region of target genes and regulating
CC       positively or negatively their expression. Oncogene which plays a role
CC       in development, cell proliferation and differentiation. May also play a
CC       role in apoptosis through regulation of the JNK and TGF-beta signaling.
CC       Involved in hematopoiesis. {ECO:0000269|PubMed:10856240,
CC       ECO:0000269|PubMed:11568182, ECO:0000269|PubMed:15897867,
CC       ECO:0000269|PubMed:16462766, ECO:0000269|PubMed:19767769,
CC       ECO:0000269|PubMed:9665135}.
CC   -!- FUNCTION: [Isoform 7]: Displays histone methyltransferase activity and
CC       monomethylates 'Lys-9' of histone H3 (H3K9me1) in vitro. Probably
CC       catalyzes the monomethylation of free histone H3 in the cytoplasm which
CC       is then transported to the nucleus and incorporated into nucleosomes
CC       where SUV39H methyltransferases use it as a substrate to catalyze
CC       histone H3 'Lys-9' trimethylation. Likely to be one of the primary
CC       histone methyltransferases along with PRDM16 that direct cytoplasmic
CC       H3K9me1 methylation. {ECO:0000250|UniProtKB:P14404}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl(9)-[histone H3] + S-adenosyl-L-methionine = H(+) +
CC         N(6)-methyl-L-lysyl(9)-[histone H3] + S-adenosyl-L-homocysteine;
CC         Xref=Rhea:RHEA:60280, Rhea:RHEA-COMP:15542, Rhea:RHEA-COMP:15546,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57856,
CC         ChEBI:CHEBI:59789, ChEBI:CHEBI:61929;
CC         Evidence={ECO:0000250|UniProtKB:P14404};
CC   -!- SUBUNIT: [Isoform 1]: Homooligomer. Interacts with SUV39H1 (via SET
CC       domain); enhances MECOM transcriptional repression activity (By
CC       similarity). Interacts with CTBP1. Interacts with SMAD3 (via MH2
CC       domain); the interaction is direct. Interacts with SMAD4; through
CC       interaction with SMAD3. Interacts with CREBBP, KAT2B and histone
CC       deacetylases. Interacts with MAPK8 and MAPK9; inhibits JNK signaling
CC       (PubMed:10856240, PubMed:11568182, PubMed:15897867, PubMed:9665135).
CC       {ECO:0000250|UniProtKB:P14404, ECO:0000269|PubMed:10856240,
CC       ECO:0000269|PubMed:11568182, ECO:0000269|PubMed:15897867,
CC       ECO:0000269|PubMed:9665135}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11568182,
CC       ECO:0000269|PubMed:15897867, ECO:0000269|PubMed:9665135}. Nucleus
CC       speckle {ECO:0000269|PubMed:11568182}. Cytoplasm
CC       {ECO:0000269|PubMed:22939622}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=8;
CC       Name=7;
CC         IsoId=Q03112-7; Sequence=Displayed;
CC       Name=1; Synonyms=Long, Evi-1a;
CC         IsoId=Q03112-1; Sequence=VSP_059479, VSP_059484;
CC       Name=2; Synonyms=Evi-1c, Mds1/Evi1;
CC         IsoId=Q03112-3; Sequence=VSP_059484;
CC       Name=4;
CC         IsoId=Q03112-4; Sequence=VSP_059480, VSP_059483, VSP_059484;
CC       Name=5;
CC         IsoId=Q03112-5; Sequence=VSP_059479;
CC       Name=6;
CC         IsoId=Q03112-6; Sequence=VSP_059479, VSP_059483;
CC       Name=8;
CC         IsoId=Q03112-8; Sequence=VSP_059484, VSP_059485, VSP_059486;
CC       Name=9; Synonyms=MDS1;
CC         IsoId=Q03112-9; Sequence=VSP_059481, VSP_059482;
CC   -!- DOMAIN: Both zinc finger regions are required for the transcriptional
CC       activation of PBX1.
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- PTM: May be acetylated by CREBBP and KAT2B.
CC       {ECO:0000269|PubMed:11568182}.
CC   -!- DISEASE: Note=A chromosomal aberration involving EVI1 is a cause of
CC       chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with
CC       RUNX1/AML1. {ECO:0000269|PubMed:8313895}.
CC   -!- DISEASE: Radioulnar synostosis with amegakaryocytic thrombocytopenia 2
CC       (RUSAT2) [MIM:616738]: An autosomal dominant disease characterized by
CC       proximal fusion of the radius and ulna resulting in extremely limited
CC       pronation and supination of the forearm, and congenital
CC       thrombocytopenia that progresses to pancytopenia.
CC       {ECO:0000269|PubMed:26581901}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving MDS1 is found in a
CC       form of acute myeloid leukemia (AML). Translocation t(3;21) with AML1.
CC       {ECO:0000269|PubMed:8643684}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage.
CC       Unable to form homooligomers, to interact with CTBP1 and SMAD3 and to
CC       repress TGF-beta signaling. {ECO:0000244|PubMed:28112733,
CC       ECO:0000269|PubMed:15897867}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB29907.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAB29907.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA that is the result of a chromosomal aberration involving EVI1 and RUNX1.; Evidence={ECO:0000305};
CC       Sequence=AAI30521.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EVI103q26ID19.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X54989; CAA38735.1; -; mRNA.
DR   EMBL; U43292; AAB05839.1; -; mRNA.
DR   EMBL; U43293; AAB05840.1; -; mRNA.
DR   EMBL; AK292865; BAF85554.1; -; mRNA.
DR   EMBL; AK304098; BAH14103.1; -; mRNA.
DR   EMBL; CR541866; CAG46664.1; -; mRNA.
DR   EMBL; CR541886; CAG46684.1; -; mRNA.
DR   EMBL; BX640908; CAE45952.1; -; mRNA.
DR   EMBL; BX647613; CAI46086.1; -; mRNA.
DR   EMBL; AC007849; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC024099; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069220; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC074033; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC078985; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF457717; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78549.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78553.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78556.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78557.1; -; Genomic_DNA.
DR   EMBL; BC031019; AAH31019.1; -; mRNA.
DR   EMBL; BC069498; AAH69498.1; -; mRNA.
DR   EMBL; BC130520; AAI30521.1; ALT_INIT; mRNA.
DR   EMBL; BC143951; AAI43952.1; -; mRNA.
DR   EMBL; BC143952; AAI43953.1; -; mRNA.
DR   EMBL; S69002; AAB29907.1; ALT_SEQ; mRNA.
DR   EMBL; S82592; AAB37456.1; -; mRNA.
DR   CCDS; CCDS3205.1; -. [Q03112-1]
DR   CCDS; CCDS54669.1; -. [Q03112-5]
DR   CCDS; CCDS54670.1; -. [Q03112-4]
DR   PIR; A60191; A60191.
DR   PIR; S41705; S41705.
DR   RefSeq; NP_001098547.3; NM_001105077.3. [Q03112-4]
DR   RefSeq; NP_001098548.2; NM_001105078.3. [Q03112-1]
DR   RefSeq; NP_001157471.1; NM_001163999.1. [Q03112-6]
DR   RefSeq; NP_001157472.1; NM_001164000.1. [Q03112-5]
DR   RefSeq; NP_001192123.1; NM_001205194.1. [Q03112-1]
DR   RefSeq; NP_004982.2; NM_004991.3. [Q03112-3]
DR   RefSeq; NP_005232.2; NM_005241.3. [Q03112-1]
DR   RefSeq; XP_005247272.1; XM_005247215.3.
DR   RefSeq; XP_005247276.1; XM_005247219.2.
DR   RefSeq; XP_005247277.1; XM_005247220.2.
DR   RefSeq; XP_005247278.1; XM_005247221.2.
DR   RefSeq; XP_005247280.1; XM_005247223.2.
DR   RefSeq; XP_016861363.1; XM_017005874.1. [Q03112-4]
DR   RefSeq; XP_016861364.1; XM_017005875.1.
DR   RefSeq; XP_016861365.1; XM_017005876.1.
DR   PDB; 6BW3; X-ray; 2.20 A; B/D=1-12.
DR   PDBsum; 6BW3; -.
DR   SMR; Q03112; -.
DR   BioGrid; 108423; 55.
DR   DIP; DIP-38639N; -.
DR   ELM; Q03112; -.
DR   IntAct; Q03112; 20.
DR   MINT; Q03112; -.
DR   STRING; 9606.ENSP00000264674; -.
DR   iPTMnet; Q03112; -.
DR   PhosphoSitePlus; Q03112; -.
DR   BioMuta; MECOM; -.
DR   DMDM; 145559472; -.
DR   jPOST; Q03112; -.
DR   MassIVE; Q03112; -.
DR   PaxDb; Q03112; -.
DR   PeptideAtlas; Q03112; -.
DR   PRIDE; Q03112; -.
DR   ProteomicsDB; 17508; -.
DR   ProteomicsDB; 58186; -. [Q03112-1]
DR   ProteomicsDB; 58187; -. [Q03112-3]
DR   ProteomicsDB; 58188; -. [Q03112-4]
DR   ProteomicsDB; 58189; -. [Q03112-5]
DR   ProteomicsDB; 58190; -. [Q03112-6]
DR   ProteomicsDB; 59462; -.
DR   DNASU; 2122; -.
DR   Ensembl; ENST00000264674; ENSP00000264674; ENSG00000085276. [Q03112-4]
DR   Ensembl; ENST00000464456; ENSP00000419770; ENSG00000085276. [Q03112-5]
DR   Ensembl; ENST00000468789; ENSP00000419995; ENSG00000085276. [Q03112-1]
DR   Ensembl; ENST00000494292; ENSP00000417899; ENSG00000085276. [Q03112-7]
DR   Ensembl; ENST00000628990; ENSP00000486104; ENSG00000085276. [Q03112-1]
DR   Ensembl; ENST00000651503; ENSP00000498411; ENSG00000085276. [Q03112-3]
DR   GeneID; 2122; -.
DR   KEGG; hsa:2122; -.
DR   UCSC; uc003ffi.3; human. [Q03112-7]
DR   CTD; 2122; -.
DR   DisGeNET; 2122; -.
DR   GeneCards; MECOM; -.
DR   HGNC; HGNC:3498; MECOM.
DR   HPA; HPA046537; -.
DR   MalaCards; MECOM; -.
DR   MIM; 165215; gene.
DR   MIM; 600049; gene.
DR   MIM; 616738; phenotype.
DR   neXtProt; NX_Q03112; -.
DR   OpenTargets; ENSG00000085276; -.
DR   Orphanet; 402020; Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
DR   Orphanet; 52688; Myelodysplastic syndrome.
DR   Orphanet; 71289; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome.
DR   PharmGKB; PA27912; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   GeneTree; ENSGT00940000157208; -.
DR   InParanoid; Q03112; -.
DR   KO; K04462; -.
DR   OMA; PNMWHSM; -.
DR   OrthoDB; 406002at2759; -.
DR   PhylomeDB; Q03112; -.
DR   TreeFam; TF315309; -.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   SignaLink; Q03112; -.
DR   SIGNOR; Q03112; -.
DR   ChiTaRS; MECOM; human.
DR   GeneWiki; MECOM; -.
DR   GenomeRNAi; 2122; -.
DR   Pharos; Q03112; Tbio.
DR   PRO; PR:Q03112; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q03112; protein.
DR   Bgee; ENSG00000085276; Expressed in endometrium and 220 other tissues.
DR   ExpressionAtlas; Q03112; baseline and differential.
DR   Genevisible; Q03112; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0046974; F:histone methyltransferase activity (H3-K9 specific); ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; ISS:UniProtKB.
DR   GO; GO:0070828; P:heterochromatin organization; ISS:UniProtKB.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00096; zf-C2H2; 8.
DR   SMART; SM00317; SET; 1.
DR   SMART; SM00355; ZnF_C2H2; 10.
DR   SUPFAM; SSF57667; SSF57667; 5.
DR   PROSITE; PS50280; SET; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 8.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 10.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Chromosomal rearrangement; Cytoplasm;
KW   Developmental protein; Differentiation; Disease mutation; DNA-binding;
KW   Isopeptide bond; Metal-binding; Methyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..1230
FT                   /note="Histone-lysine N-methyltransferase MECOM"
FT                   /id="PRO_0000047273"
FT   DOMAIN          78..190
FT                   /note="SET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT   ZN_FING         209..236
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         263..285
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         291..313
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         319..342
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         348..370
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         376..398
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         405..427
FT                   /note="C2H2-type 7; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         912..934
FT                   /note="C2H2-type 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         940..963
FT                   /note="C2H2-type 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         969..991
FT                   /note="C2H2-type 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          189..440
FT                   /note="Interaction with MAPK9, SMAD3 and probably SUV39H1"
FT                   /evidence="ECO:0000269|PubMed:10856240"
FT   MOTIF           609..622
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           741..745
FT                   /note="CTBP-binding motif 1"
FT                   /evidence="ECO:0000250"
FT   MOTIF           772..776
FT                   /note="CTBP-binding motif 2"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        1065..1116
FT                   /note="Asp/Glu-rich (acidic)"
FT   MOD_RES         624
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         726
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         740
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P14404"
FT   MOD_RES         1037
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1039
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   CROSSLNK        99
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        190
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25772364, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        249
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        292
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        367
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        374
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        430
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        523
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        543
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        547
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        555
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25772364, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        622
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        635
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        663
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        685
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25772364, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        721
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25772364, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        731
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        732
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        735
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        749
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        752
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        760
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        787
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        800
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        801
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        835
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        844
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        846
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        877
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25772364,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1018
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1053
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25772364,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1056
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1120
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1127
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1132
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25772364, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1149
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1152
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25772364, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1176
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        1184
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        Q03112-1:658
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        Q03112-3:846
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        Q03112-4:202
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        Q03112-4:723
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        Q03112-6:138
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        Q03112-8:846
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1..188
FT                   /note="Missing (in isoform 1, isoform 5 and isoform 6)"
FT                   /id="VSP_059479"
FT   VAR_SEQ         1..125
FT                   /note="MRSKGRARKLATNNECVYGNYPEIPLEEMPDADGVASTPSLNIQEPCSPATS
FT                   SEAFTPKEGSPYKAPIYIPDDIPIPAEFELRESNMPGAGLGIWTKRKIEVGEKFGPYVG
FT                   EQRSNLKDPSYGWE -> M (in isoform 4)"
FT                   /id="VSP_059480"
FT   VAR_SEQ         126..169
FT                   /note="ILDEFYNVKFCIDASQPDVGSWLKYIRFAGCYDQHNLVACQIND -> VHLP
FT                   RSRRVSVHSWLYLGKRSSDVGIAFSQADVYMPGLQCAFLS (in isoform 9)"
FT                   /id="VSP_059481"
FT   VAR_SEQ         170..1230
FT                   /note="Missing (in isoform 9)"
FT                   /id="VSP_059482"
FT   VAR_SEQ         326
FT                   /note="K -> KQ (in isoform 4 and isoform 6)"
FT                   /id="VSP_059483"
FT   VAR_SEQ         859
FT                   /note="Q -> QFQLPDQRTW (in isoform 1, isoform 4, isoform 8
FT                   and isoform 2)"
FT                   /id="VSP_059484"
FT   VAR_SEQ         939..945
FT                   /note="PYRCKYC -> LKNKDLQ (in isoform 8)"
FT                   /id="VSP_059485"
FT   VAR_SEQ         946..1230
FT                   /note="Missing (in isoform 8)"
FT                   /id="VSP_059486"
FT   VARIANT         120
FT                   /note="P -> S (in dbSNP:rs7622799)"
FT                   /id="VAR_051183"
FT   VARIANT         295
FT                   /note="Q -> R (in dbSNP:rs34896995)"
FT                   /id="VAR_061928"
FT   VARIANT         929
FT                   /note="R -> W (in RUSAT2; alters transcriptional
FT                   regulation; dbSNP:rs864309724)"
FT                   /evidence="ECO:0000269|PubMed:26581901"
FT                   /id="VAR_076308"
FT   VARIANT         930
FT                   /note="H -> R (in RUSAT2; alters transcriptional
FT                   regulation; dbSNP:rs864309723)"
FT                   /evidence="ECO:0000269|PubMed:26581901"
FT                   /id="VAR_076309"
FT   VARIANT         935
FT                   /note="T -> A (in RUSAT2; alters transcriptional
FT                   regulation; dbSNP:rs864309722)"
FT                   /evidence="ECO:0000269|PubMed:26581901"
FT                   /id="VAR_076310"
FT   MUTAGEN         743..744
FT                   /note="DL->AS: Partial loss of interaction with CTBP1. Loss
FT                   of interaction with CTBP1; when associated with 586-A-S-
FT                   775"
FT                   /evidence="ECO:0000269|PubMed:11568182"
FT   MUTAGEN         774..775
FT                   /note="DL->AS: Partial loss of interaction with CTBP1. Loss
FT                   of interaction with CTBP1; when associated with 555-A-S-
FT                   744"
FT                   /evidence="ECO:0000269|PubMed:11568182"
FT   CONFLICT        126..127
FT                   /note="IL -> VR (in Ref. 2; AAB05840)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        208
FT                   /note="Q -> R (in Ref. 6; CAE45952)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        363
FT                   /note="L -> P (in Ref. 6; CAE45952)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        489
FT                   /note="F -> S (in Ref. 4; BAF85554)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        491
FT                   /note="F -> V (in Ref. 1; CAA38735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        631
FT                   /note="S -> P (in Ref. 6; CAI46086)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        731
FT                   /note="K -> R (in Ref. 6; CAE45952)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        909
FT                   /note="K -> R (in Ref. 4; BAF85554)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        920
FT                   /note="I -> V (in Ref. 6; CAI46086)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        975
FT                   /note="D -> Y (in Ref. 1; CAA38735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1054
FT                   /note="D -> E (in Ref. 1; CAA38735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1060
FT                   /note="T -> P (in Ref. 1; CAA38735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1085
FT                   /note="N -> Y (in Ref. 1; CAA38735)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1171
FT                   /note="V -> A (in Ref. 4; BAF85554)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1187..1191
FT                   /note="AYAMM -> VQIFP (in Ref. 11; AAB37456)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1192
FT                   /note="L -> P (in Ref. 6; CAE45952)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1230 AA;  138136 MW;  49E9B7CBCD422042 CRC64;
     MRSKGRARKL ATNNECVYGN YPEIPLEEMP DADGVASTPS LNIQEPCSPA TSSEAFTPKE
     GSPYKAPIYI PDDIPIPAEF ELRESNMPGA GLGIWTKRKI EVGEKFGPYV GEQRSNLKDP
     SYGWEILDEF YNVKFCIDAS QPDVGSWLKY IRFAGCYDQH NLVACQINDQ IFYRVVADIA
     PGEELLLFMK SEDYPHETMA PDIHEERQYR CEDCDQLFES KAELADHQKF PCSTPHSAFS
     MVEEDFQQKL ESENDLQEIH TIQECKECDQ VFPDLQSLEK HMLSHTEERE YKCDQCPKAF
     NWKSNLIRHQ MSHDSGKHYE CENCAKVFTD PSNLQRHIRS QHVGARAHAC PECGKTFATS
     SGLKQHKHIH SSVKPFICEV CHKSYTQFSN LCRHKRMHAD CRTQIKCKDC GQMFSTTSSL
     NKHRRFCEGK NHFAAGGFFG QGISLPGTPA MDKTSMVNMS HANPGLADYF GANRHPAGLT
     FPTAPGFSFS FPGLFPSGLY HRPPLIPASS PVKGLSSTEQ TNKSQSPLMT HPQILPATQD
     ILKALSKHPS VGDNKPVELQ PERSSEERPF EKISDQSESS DLDDVSTPSG SDLETTSGSD
     LESDIESDKE KFKENGKMFK DKVSPLQNLA SINNKKEYSN HSIFSPSLEE QTAVSGAVND
     SIKAIASIAE KYFGSTGLVG LQDKKVGALP YPSMFPLPFF PAFSQSMYPF PDRDLRSLPL
     KMEPQSPGEV KKLQKGSSES PFDLTTKRKD EKPLTPVPSK PPVTPATSQD QPLDLSMGSR
     SRASGTKLTE PRKNHVFGGK KGSNVESRPA SDGSLQHARP TPFFMDPIYR VEKRKLTDPL
     EALKEKYLRP SPGFLFHPQM SAIENMAEKL ESFSALKPEA SELLQSVPSM FNFRAPPNAL
     PENLLRKGKE RYTCRYCGKI FPRSANLTRH LRTHTGEQPY RCKYCDRSFS ISSNLQRHVR
     NIHNKEKPFK CHLCDRCFGQ QTNLDRHLKK HENGNMSGTA TSSPHSELES TGAILDDKED
     AYFTEIRNFI GNSNHGSQSP RNVEERMNGS HFKDEKALVT SQNSDLLDDE EVEDEVLLDE
     EDEDNDITGK TGKEPVTSNL HEGNPEDDYE ETSALEMSCK TSPVRYKEEE YKSGLSALDH
     IRHFTDSLKM RKMEDNQYSE AELSSFSTSH VPEELKQPLH RKSKSQAYAM MLSLSDKESL
     HSTSHSSSNV WHSMARAAAE SSAIQSISHV
//
